Epic Sciences company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

epicsciences.com

Founded Year

2008

Stage

Series F | Alive

Total Raised

$192M

Last Raised

$43M | 1 mo ago

About Epic Sciences

Epic Sciences develops and markets diagnostics to guide therapy selection and monitor disease progression, personalizing and advancing the treatment and management of prostate and breast cancers. The company's liquid biopsy platform offers proprietary cell analysis capabilities, as well as cell-free analysis to provide analysis and insights, including comprehensive cancer profiling. Using its full-service CAP/CLIA-accredited laboratory and research support services, Epic Sciences partners with pharmaceutical companies and cancer centers around the world to improve patient outcomes. It was founded in 2008 and is based in San Diego, California.

Epic Sciences Headquarter Location

9381 Judicial Drive Suite 200

San Diego, California, 92121,

United States

858-356-6610

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Epic Sciences

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Epic Sciences in 1 CB Insights research brief, most recently on Oct 10, 2019.

Expert Collections containing Epic Sciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Epic Sciences is included in 3 Expert Collections, including Cancer.

C

Cancer

3,710 items

Products/services that analyze tumor-derived biomarkers (ctDNA, CTCs, exosomes) in blood/urine/other non-invasive liquid specimens to detect cancer earlier, guide treatment, and monitor progress. *Data fields manually updated as new information becomes available.'

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

B

Biopharma Tech

260 items

Epic Sciences Patents

Epic Sciences has filed 26 patents.

The 3 most popular patent topics include:

  • Oncology
  • Clusters of differentiation
  • Experimental cancer drugs
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/11/2019

5/24/2022

Transcription factors, Cell biology, Clusters of differentiation, Molecular biology, Oncology

Grant

Application Date

12/11/2019

Grant Date

5/24/2022

Title

Related Topics

Transcription factors, Cell biology, Clusters of differentiation, Molecular biology, Oncology

Status

Grant

Latest Epic Sciences News

Epic Advances Liquid Biopsy

Jun 27, 2022

Epic Advances Liquid Biopsy   On June 2, the company announced it had completed a $43 million first close of its Series F financing round, led by Arsenal Capital Partners with support from existing investors Blue Ox Healthcare Partners, Deerfield Management and Labcorp. Lloyd SandersPresident & CEOEpic Sciences, Inc. “We are extremely proud to have a world-class group of strategic partners backing us to meet the growing demand for Epic’s liquid biopsy offerings,” said Lloyd Sanders, president and CEO of Epic Sciences. “We are continuing to innovate testing for both the research and clinical markets. Our biopharma partners are driving our presence into drug development efforts and an increasing number of clinical trials, while we continue to see growing excitement from practicing clinical oncologists for DefineMBC and future tests.”     In May, Epic added to its CLIA Library DefineMBC – the company’s novel blood-based test for metastatic breast cancer. “The test is intended to be used when tissue biopsy is inaccessible or infeasible,” Sanders said. “The test can provide insight on how a patient’s metastatic breast cancer is evolving and becoming more heterogeneous over time and what options such as HER2 targeted therapies, antibody drug conjugates, immunotherapies, or others may be the next best treatment or clinical trial for a patient.”   DefineMBC has been reporting patient results since April and has shown sensitivity, specificity, accuracy and precision in detecting the presence of cancer. Epic Sciences has partnered with over 20 US-based medical oncologists to further refine reporting of test results, as well as case study reviews to finalize formatting and communication of findings. The company is also collaborating with eight academic institutions and the top trial co-operative groups as well as drug development companies to generate data in the context of current of future clinical scenarios. “With growing demand for liquid biopsy solutions from medical oncologists, researchers, drug developers and patients, Epic will use the new capital to accelerate the commercial launch of DefineMBC and continue to drive comprehensive liquid biopsy into key development trials,” Sanders said. “The company is also recruiting top talent to scale technical operations and scientific support functions.” James Rothman Ph.D.Advisory Board ChairArsenal Healthcare New Talent on Board   The funding round is also bringing in notable expertise to the company’s board of directors. James Rothman Ph.D. is the chair of Arsenal’s Healthcare Advisory Board and a renowned cell biologist and Nobel Laureate who was formerly chief scientist of GE Healthcare. And Richard Eglen, Ph.D. a senior advisor of Arsenal who brings decades of industry leadership experience with companies such as PerkinElmer, Roche Bioscience and Corning Inc.   “What is most exciting about Epic’s approach is the ability to derive valuable insights from data at the cellular and subcellular level for both drug developers and clinicians in oncology,” said Dr. Rothman, who also serves as the Sterling Professor and chair of the Department of Cell Biology at Yale University School of Medicine. In addition to DefineMBC, Epic also offers a CLIA laboratory test for the3 detection of prostate cancer, AR-V7, which is marketed by Exact Sciences as Oncotype DX AR-V7 Nucleus Detect. The company is also currently developing a portfolio of over 35 research assays and plans to offer its PSMA liquid biopsy assay as well as other capabilities for prostate cancer patient testing from its CLIA laboratory in 2023.

Epic Sciences Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Epic Sciences Rank

  • When was Epic Sciences founded?

    Epic Sciences was founded in 2008.

  • Where is Epic Sciences's headquarters?

    Epic Sciences's headquarters is located at 9381 Judicial Drive, San Diego.

  • What is Epic Sciences's latest funding round?

    Epic Sciences's latest funding round is Series F.

  • How much did Epic Sciences raise?

    Epic Sciences raised a total of $192M.

  • Who are the investors of Epic Sciences?

    Investors of Epic Sciences include Blue Ox Capital, Deerfield Management, LabCorp, Arsenal Capital Partners, Paycheck Protection Program and 19 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.